Holen Sie sich die Stockscreener-App
4.66
1.53%
0.07
Handel nachbörslich:
4.59
-0.07
-1.50%
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena’s (PRTA) “Underperform” Rating Reaffirmed at Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Prothena (NASDAQ:PRTA) Price Target Cut to $29.00 by Analysts at JMP Securities - Defense World
Prothena (NASDAQ:PRTA) Lowered to Hold Rating by Jefferies Financial Group - Defense World
Prothena (NASDAQ:PRTA) Given New $14.00 Price Target at HC Wainwright - Defense World
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA) - Defense World
Prothena (PRTA) Shares Plunge After Key Trial Setback - GuruFocus
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place (PRTA) - Seeking Alpha
Peninsula biotech Prothena falters — again — and layoffs are on the waySan Francisco Business Times - The Business Journals
Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued - marketscreener.com
Prothena Corp (PRTA) Downgraded by Oppenheimer | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results - Insider Monkey
Prothena stock hits 52-week low amid downgrades (PRTA:NASDAQ) - Seeking Alpha
Prothena Corp (PRTA) Sees Target Price Reduction by Piper Sandle - GuruFocus
Piper Sandler cuts Prothena stock target to $81 from $110 By Investing.com - Investing.com UK
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Cantor Fitzgerald cuts Prothena stock rating to Neutral By Investing.com - Investing.com UK
Prothena Corp (PRTA) Target Price Slashed by JMP Securities | PRTA Stock News - GuruFocus
Prothena (PRTA) Downgraded Following Unsuccessful Phase 3 Trial - GuruFocus
Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts - Benzinga
Prothena Corp (PRTA) Analyst Update: Price Target Significantly Lowered | PRTA Stock News - GuruFocus
Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32 - marketscreener.com
Prothena Corp (PRTA) Price Target Lowered by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Prothena stock price target cut to $14 at H.C. Wainwright By Investing.com - Investing.com UK
Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating - marketscreener.com
Prothena (PRTA) Price Target Slashed Following Clinical Trial Ou - GuruFocus
Prothena (PRTA) Faces Price Target Cut Following Trial Results | PRTA Stock News - GuruFocus
Prothena (PRTA) Target Price Slashed Following Study Setback | P - GuruFocus
Prothena (PRTA) Target Price Slashed Following Study Setback | PRTA Stock News - GuruFocus
Prothena (PRTA) Faces Setback with AFFIRM-AL Trial Results | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena (PRTA) Following Study Setback | P - GuruFocus
Prothena (PRTA) Downgraded by Oppenheimer After Trial Results | - GuruFocus
Oppenheimer cuts Prothena stock rating after trial setback By Investing.com - Investing.com South Africa
Jefferies cuts Prothena stock rating to hold, slashes target to $6 By Investing.com - Investing.com UK
Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint - Yahoo Finance
Prothena’s SWOT analysis: biotech stock’s high-risk, high-reward pipeline By Investing.com - Investing.com Nigeria
Prothena’s SWOT analysis: biotech stock’s high-risk, high-reward pipeline - Investing.com
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):